JCT  Vol.5 No.6 , May 2014
A Clinic-Epidemilogical Study of Cases of Locally Advanced Non Small Cell Lung Cancer (NSCLC) That Received Radiotherapy at NCI Cairo in the Period from 2001-2010
ABSTRACT

Purpose: This work was to study the clinic-epidemiological characteristics of patients with locally advanced NCSLC and to analyze their prognostic factors and also the results of different treatment modalities for local control and their effect on overall survival (OAS). Materials and Methods: This is a retrospective study including 121 patients with primary locally advanced NSCLC diagnosed between 2001 and 2010 at the radiotherapy department , National Cancer Institute, Cairo University, Egypt. Results: The study showed significant correlation between the tumor size < 7 cm, old age > 60, moderately differentiated tumors G2 and treatment outcomes; better locoregional control and better survival rates. On the opposite side poorly differentiated tumors G3, tumor size > 7 cm had the worst locoregional control and survival rates. The study also showed significant statistical correlation between treatment modality, locoregional control and survival rates. Patients who were treated by either concommitent chemo-radiotherapy or sequential chemo-radiotherapy had better local control compared to other patients who were treated by radical radiotherapy, and they also had the best survival rates among all the other treatment groups. The average 6 months OAS rates for all studied patients were 60.3% while 12 months survival rates were 38.8%. The median OAS was 7 months. Conclusions: From the present study, we concluded that concomitant chemo-radiotherapy is the treatment of choice for locally advanced non small cell lung cancer; also we concluded that better performance status and higher hemoglobin levels have better treatment outcome in these cases.


Cite this paper
Lotayef, M. , Taher, A. , Attia, H. , Nasr, A. , Hossieny, H. , Mahmoud, M. and Essam, N. (2014) A Clinic-Epidemilogical Study of Cases of Locally Advanced Non Small Cell Lung Cancer (NSCLC) That Received Radiotherapy at NCI Cairo in the Period from 2001-2010. Journal of Cancer Therapy, 5, 542-551. doi: 10.4236/jct.2014.56062.
References
[1]   Mokhtar, N., Gouda, I. and Adel, I. (2004) Cancer Pathology Registry 2003-2004 and Time Trend Analysis.

[2]   Curran, W.J., Scott, C., Langer, C., et al. (2003) Long-Term Benefit Is Observed in a Phase III Comparison of Sequential vs Concurrent Chemoradiation for Patients with Unresected Stage III Non Small Cell Lung Cancer: RTOG 9410. Journal of the National Cancer Institute, 22, 621a.

[3]   Kong, F.M., Zhao, L. and Hayman, J.A. (2006) The Role of Radiation Therapy in Thoracic Tumors. Hematology/Oncology Clinics of North America, 20, 363-400. http://dx.doi.org/10.1016/j.hoc.2006. 01.021

[4]   Ries, L.A.G., Harkins, D., Krapcho, M., Mariotto, A., Miller, B.A., Feuer, E.J., Clegg, L., Eisner, M.P., Horner, M.J., Howlader, N., Hayat, M., Hankey, B.F. and Edwards, B.K. (Eds.) (2006) SEER Cancer Statistics Review, 1975-2003. National Cancer Institute. Bethesda.

[5]   Adamo, M.B., Johnson, C.H., Ruhl, J.L. and Dickie, L.A. (Eds.) (2011) SEER Program Coding and Staging Manual. National Cancer Institute, Bethesda, NIH Publication Number 11-5581.

[6]   Molina, J.R., Yang, P. and Cassivi, S.D. (2008) Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clinic Proceedings, 83, 584-594.
http://dx.doi.org/10.4065/83.5.584

[7]   Galluzzi, S. and Payne, P.M. (1955) Bronchial Carcinoma: A Statistical Study of 741 Necropsies with Special Reference to the Distribution of Blood-Borne Metastases. British Journal of Cancer, 9, 511. http://dx.doi.org/10.1038/bjc.1955.53

[8]   Kuchuk, M., Addison, C.L., Clemons, M., Kuchuk, I. and Wheatley-Price, P. (2013) Incidence and Consequences of Bone Metastases in Lung Cancer Patients. Journal of Bone Oncology, 2, 22-29. http://dx.doi.org/10.1016/j.jbo.2012.12.004

[9]   Bezjak, A., Dixon, P., Brundage, M., Tu, D., Palmer, M.J., Blood, P., Grafton, C., Lochrin, C., Leong, C., Mulroy, L., Smith, C., Wright, J. and Pater, J.L. (2002) Randomized Phase III Trial of Single Versus Fractionated Thoracic Radiation in the Palliation of Patients with Lung Cancer (NCIC CTG SC.15). International Journal of Radiation Oncology* Biology*Physics, 54, 719-728.
http://dx.doi.org/10.1016/S0360-3016(02)02989-9

[10]   Sculier, J.P., Chansky, K., Crowley, J.J., et al. (2008) The Impact of Additional Prognostic Factors on Survival and Their Relationship with the Anatomical Extent of Disease Expressed by the 6th Edition of the TNM Classification of Malignant Tumors and the Proposals for the 7th Edition. Journal of Thoracic Oncology, 3, 457.

[11]   Takise, A., Kodama, T., Shimosato, Y., Watanabe, S. and Suemasu, K. (1988) Histopathologic Prognostic Factors in Adenocarcinomas of the Peripheral Lung Less Than 2 cm in Diameter. Cancer, 61, 2083-2088.
http://dx.doi.org/10.1002/1097-0142(19880515)61:10<2083::AID-CNCR2820611025>3.0.CO;2-U

[12]   Groome, P.A., Bolejack, V., Crowley, J.J., Kennedy, C., Krasnik, M., Sobin, L.H., Goldstraw, P., IASLC International Staging Committee; Cancer Research and Biostatistics, Observers to the Committee and Participating Institutions (2007) The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours. Journal of Thoracic Oncology, 2, 694-705. http://dx.doi.org/10.1097/jto.0b013e31812d05d5

[13]   Jeremic, B., Milicic, B., et al. (2012) Concurrent Hyperfractionated Radiation Therapy and Chemotherapy in Locally Advanced (Stage III) Non-Small-Cell Lung Cancer: Single Institution Experience with 600 Patients. International Journal of Radiation Oncology*Biology*Physics, 1157, 1163.

[14]   Fournel, P., Robinet, G., Thomas, P., Souquet, P.-J., Léna, H., Vergnenégre, A., Delhoume, J.-Y., Le Treut, J., Silvani, J.-A., Dansin, E., Bozonnat, M.-C., Daurés, J.-P., Mornex, F. and Pérol, M. (2005) Randomized Phase III Trial of Sequential Chemoradiotherapy Compared with Concurrent Chemoradiotherapy in Locally Advanced Nonsmall-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d’OncologieThoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. Journal of Clinical Oncology, 23, 5910-5917. http://dx.doi.org/10.1200/JCO.2005.03.070

[15]   Zatloukal, P., Petruzelka, L., Zemanova, M., Havel, L., Janku, F., Judas, L., Kubik, A., Krepela, E., Fiala, P. and Pecen, L. (2004) Concurrent versus Sequential Chemoradiotherapy with Cisplatin and Vinorelbine in Locally Advanced Non-small Cell Lung Cancer: A Randomized Study. Lung Cancer, 46, 87-98. http://dx.doi.org/10.1016/j.lungcan.2004.03.004

[16]   Sause, W., Kolesar, P., Taylor IV, S., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran Jr., W., Byhardt, R., Dar, A.R. and Turrisi 3rd, A. (2000) Final Results of Phase III Trial in Regionally Advanced Unresectable Non-Small Cell Lung Cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest, 117, 358-364.
http://dx.doi.org/10.1378/chest.117.2.358

[17]   Kim, D.W., Shyr, Y., Chen, H., Akerley, W., Johnson, D.H. and Choy, H. (2005) Response to Combined Modality Therapy Correlates with Survival in Locally Advanced Non-Small-Cell Lung Cancer. International Journal of Radiation Oncology*Biology*Physics, 63, 1029-1036.
http://dx.doi.org/10.1016/j.ijrobp.2005. 03.055

[18]   de Cos Escuín, J.S., Delgado, I.U., Rodríguez, J.C., López, M.J., Vicente, C.D. and Miranda, JA.R. (2007) Stage IIIA and IIIB Non-Small Cell Lung Cancer: Results of Chemotherapy Combined With Radiation Therapy and Analysis of Prognostic Factors. Archivos de Bronconeumología, 43, 358-365.

 
 
Top